S-1/A: Jupiter Neurosciences Files for $11 Million IPO to Advance Parkinson's Drug and Expand in Asia

Jupiter Neurosciences aims to raise capital through an IPO to fund the development of its Parkinson's drug, JOTROL, and expand its business operations in Southeast Asia.

Summary

• Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, has filed for an initial public offering (IPO) to raise $11 million.
• The company plans to use the funds to advance its drug candidate, JOTROL, for Parkinson's disease and to expand its business in Southeast Asia.
• JOTROL is a resveratrol-based drug targeting neuro-inflammation, with potential applications in rare diseases like Mucopolysaccharidoses Type 1 (MPS-1), Friedreich's Ataxia, and MELAS, as well as larger indications like Parkinson's and Alzheimer's.
• The IPO includes an offering of 2,750,000 shares with an expected price range of $4.00 to $5.00 per share.
• The company intends to list its common stock on the Nasdaq Capital Market under the symbol 'JUNS'.
• A portion of the IPO proceeds will be used to repay debt, fund R&D, cover license fees, and support clinical trials and service agreements in Southeast Asia.
• The offering also registers the resale of 3,600,000 shares by selling stockholders, with no proceeds going to the company from these sales.
• Jupiter Neurosciences faces risks including limited operating history, dependence on JOTROL's success, clinical trial uncertainties, competition, and the need for additional capital.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern due to recurring losses and dependence on financing.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the potential of JOTROL and strategic market expansion, the company's financial situation and dependence on future funding raise concerns.

Positives

• JOTROL has shown promise in preclinical studies and a Phase I trial, indicating potential to deliver therapeutically effective doses of resveratrol without severe side effects.
• The company has secured a worldwide license for JOTROL and has patents granted in key markets including the USA, Europe, Japan, and China.
• The company is strategically targeting the Asian market, where resveratrol is recognized in Traditional Chinese Medicine, and has established service agreements to facilitate market entry.
• The company has a Scientific Advisory Board with experienced members from leading institutions.
• The company has received a full grant from the National Institute on Aging (NIA) for its Phase I study.

Negatives

• The company has a limited operating history and has not generated any revenue from product sales to date.
• The company has incurred significant net losses since inception and expects to continue to incur significant net losses for the foreseeable future.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company is substantially dependent on the success of its product candidate, JOTROL.
• The company faces significant competition in the pharmaceutical industry.
• The company relies on third parties to conduct its preclinical studies, clinical trials, and manufacturing.
• The price of the company's common stock could be subject to rapid and substantial volatility.

Risks

• The company's ability to generate revenue and achieve profitability depends significantly on its ability to achieve several objectives relating to the discovery, development and commercialization of its product candidate.
• Even if this offering is successful, the company will require substantial additional capital to finance its operations.
• The company's substantial amount of indebtedness may adversely affect its cash flow and its ability to operate its business, remain in compliance with debt covenants and make payments on its indebtedness.
• The company's outstanding Secured Note provides its Secured Lender with liens on substantially all of its assets, including its intellectual property, and contains financial covenants and other restrictions on its actions, which may cause significant risks to its stockholders and may impact its ability to pursue certain transactions and operate its business.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
• The company is planning on entering into a Service Agreement with DOMINANT TREASURE HEALTH COMPANY LIMITED with respect to strategic services in Asia immediately following the completion of the public offering, the fees payable by the Company pursuant to which, are non-refundable and not tied to any milestones or performance, and the foregoing nature of such fees, could have a material negative impact on our business, financial condition and operating results.
• The price of the company's common stock could be subject to rapid and substantial volatility.
• As a result of the resale of shares of common stock by Selling Stockholders being a large volume of shares and potentially at different pricing after the initial fixed price, there is a potential for price volatility or depreciation for investors in the initial public offering.

Future Outlook

The company plans to use the net proceeds from the offering to fund a Proof-of-Concept clinical trial of JOTROL in patients with Parkinsons Disease, establish a presence in South-East Asia through service agreements, and advance the manufacturing of JOTROL clinical trial supplies. The company also intends to seek collaborations with future licensees and marketing partners, especially in markets outside the United States.

Management Comments

• Management has concluded that the company's historical recurring losses from operations and negative cash flows from operations as well as its dependence on securing private equity and other financings raise substantial doubt about its ability to continue as a going concern.
• Management believes that the company's structure with a core management team that has experience in the utilization of outside resources makes it possible for the company to efficiently execute several programs simultaneously in a cost-effective way.

Industry Context

The announcement highlights the increasing interest in resveratrol as a therapeutic strategy, particularly in the Asian market, and the growing Traditional Chinese Medicine (TCM) market. The company is positioning itself to capitalize on these trends through strategic partnerships and out-licensing deals.

Comparison to Industry Standards

• The document mentions Reata Pharmaceuticals' recent FDA approval for Omaveloxolone, a treatment for Friedreich's ataxia, and Biogen's subsequent acquisition of Reata for $7.3 billion, indicating the high value placed on successful rare disease treatments.
• The document references Aldurazyme, an Enzyme Replacement Therapy (ERT) for MPS I, priced at approximately $600,000 per year per patient, setting a benchmark for pricing in the rare disease market.
• The document mentions Eli Lilly's Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG has received an FDA Breakthrough Therapy designation and was recently approved by the FDA with an estimated price of $32,000 per year.

Legal Proceedings

• On July 19, 2022, Tiberend Strategic Advisors (Tiberend), an entity that the Company had previously engaged as a communications and investor relations firm, filed a summons for civil action in the District Court of Southern Florida against the Company alleging non-payment by the Company under a services agreement (the Services Agreement) with Tiberend in the amount of $130,400.

Related Party Transactions

• The company's Chief Executive Officer (CEO) has loaned the company working capital since inception.
• Accrued compensation includes partially accrued salaries to executives since inception.
• On July 21, 2022, the Company entered into a Forgiveness and Release Agreement with these executives and two consultants, who also are shareholders, to forgive accrued salary and consulting fees in the amount of $1,556,010.
• On September 29, 2023, various employees and board members agreed to forgive accrued compensation in the amount of $4,189,626.
• As of June 30, 2024, $119,550 was due to a Company wholly owned by the Company's Chief Financial Officer, who also is an option holder.
• Included in accounts payable and accrued expenses as of June 30, 2024 and December 31, 2023 are the following related party balances, respectively: expense reports due to employees $102,218 and $49,214 and annual license fee due to Aquanova AG totaling $187,500 and $150,000.

Stakeholder Impact

• The IPO could provide the company with the necessary capital to advance JOTROL and potentially benefit patients with neurological disorders.
• The company's expansion into Southeast Asia could create new business opportunities and partnerships.
• The company's financial instability and dependence on future funding raise concerns for investors and stakeholders.

Next Steps

• The company intends to use the net proceeds from this offering to repay debt, fund R&D activities, cover license fees, and support clinical trials and service agreements in Southeast Asia.
• The company plans to apply for a much smaller grant, $2.5 million, for a Proof-of-Concept study focusing on JOTROLs effect on validated biomarker.
• The company intends to follow the various opportunities closely with a particular focus on seeking available funding to accelerate research and development JOTROLs Parkinsons Disease indication.

Key Dates

Keywords

JOTROL, Parkinson's Disease, resveratrol, clinical trials, Southeast Asia, IPO, neuroinflammation, pharmaceutical, rare diseases, Alzheimer's, funding, Nasdaq